Methylene Blue Reverses Fatal Brain Malaria and Reveals Nine Blood Biomarkers
A primate study shows methylene blue treats fatal cerebral malaria and uncovers neutrophil-linked genes as diagnostic biomarkers.
Summary
Researchers used Plasmodium coatneyi-infected rhesus macaques to test methylene blue (MB) as a treatment for fatal cerebral malaria (CM) and to discover blood biomarkers. MB administered intravenously at doses of 6, 10, and 17 mg/kg twice daily from Day 7 to Day 10 post-infection successfully cleared parasites and reversed infection-driven gene expression changes in the brainstem. Transcriptomic analysis of brainstem tissue, combined with comparison across two additional datasets from infected macaque blood and P. falciparum-infected human blood, identified nine candidate genes associated with CM severity. Most of these genes are expressed in neutrophils, suggesting they could serve as accessible blood-based biomarkers to distinguish fatal from non-fatal cerebral malaria caused by P. falciparum in clinical settings.
Detailed Summary
Cerebral malaria (CM) caused by Plasmodium falciparum kills approximately 600,000 people annually and leaves up to 25% of pediatric survivors with lasting neurological deficits including cognitive impairment, seizures, and motor dysfunction. Even with the current gold-standard treatment—parenteral artesunate—mortality in African children remains around 8.5%. Rising artesunate resistance in Africa makes the search for new therapies and reliable prognostic biomarkers increasingly urgent.
To investigate both treatment and diagnostics, the research team employed P. coatneyi-infected rhesus macaques (Macaca mulatta), a non-human primate model that closely mirrors P. falciparum infection in humans. Eighteen macaques were divided into five groups: uninfected controls, infected-untreated, and three infected groups receiving methylene blue (MB) intravenously at 6, 10, or 17 mg/kg twice daily from Day 7 to Day 10 post-infection—the window when CM symptoms emerge above 15% parasitemia. Tissues including brainstem, thalamus, cerebellum, heart, kidney, and liver were harvested for whole-tissue RNA sequencing after death or euthanasia.
Differential gene expression analysis demonstrated that MB treatment effectively reversed the detrimental transcriptomic effects of P. coatneyi infection in the brainstem. Even the lowest dose (6 mg/kg), initiated at lower parasitemia and clearing parasites more slowly, achieved treatment success for all three animals in that group with clinical signs normalized by euthanasia. Higher doses cleared parasites faster. The brainstem transcriptomic signature of infected-untreated animals was substantially distinct from both uninfected controls and MB-treated animals, highlighting the severe neuroinflammatory and vascular disruption occurring in fatal CM.
To identify translatable blood biomarkers, the team cross-referenced their brainstem dataset with two additional transcriptomic datasets: P. coatneyi-infected macaque blood and P. falciparum-infected human blood. This three-way comparison yielded nine candidate genes consistently associated with CM severity across species and tissue compartments. Crucially, most of these nine genes are expressed predominantly in neutrophils, making peripheral blood a practical and minimally invasive source for biomarker measurement. These candidates hold promise as diagnostic biomarkers to differentiate fatal from non-fatal CM, prognostic markers for treatment outcomes, and tools to monitor the efficacy of adjunctive therapies in clinical trials.
The study underscores the value of the P. coatneyi primate model for preclinical CM research and positions MB—already an approved, inexpensive, widely available compound—as a viable adjunctive treatment candidate for CM pending human trials. The identified neutrophil-associated gene panel could be rapidly validated in prospective clinical cohorts, potentially transforming how clinicians triage and manage severe malaria patients.
Key Findings
- Methylene blue at 6–17 mg/kg IV twice daily reversed fatal cerebral malaria and normalized brainstem gene expression in rhesus macaques.
- Nine genes consistently associated with CM severity were identified by cross-comparing brainstem and blood transcriptomes across two species.
- Most of the nine candidate biomarker genes are predominantly expressed in neutrophils, enabling blood-based detection.
- The P. coatneyi rhesus macaque model recapitulated key P. falciparum CM features including brain sequestration and neurological decline.
- Rising artesunate resistance highlights the clinical urgency of validating methylene blue as an adjunctive CM therapy.
Methodology
Eighteen male rhesus macaques were divided into uninfected controls and four P. coatneyi-infected groups (untreated or treated with 6, 10, or 17 mg/kg MB IV twice daily, Days 7–10). Whole-tissue RNA sequencing of brainstem and other organs was performed, and differential expression results were cross-referenced with published P. coatneyi macaque blood and P. falciparum human blood transcriptomic datasets to identify conserved CM-severity biomarkers.
Study Limitations
The study used a small number of animals per group (3–5 macaques), limiting statistical power. Results are from a non-human primate model and must be validated in human clinical cohorts before clinical application. The specific mechanisms by which MB reverses brainstem transcriptomic changes remain to be fully elucidated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.